Biblio
“Associations of Physical Activity Engagement with Cerebral Amyloid-β and Tau from Midlife.”, J Alzheimers Dis, vol. 100, no. 3, pp. 935-943, 2024.
, “Apathy as a Predictor of Conversion from Mild Cognitive Impairment to Alzheimer's Disease: A Texas Alzheimer's Research and Care Consortium (TARCC) Cohort-Based Analysis.”, J Alzheimers Dis, vol. 92, no. 1, pp. 129-139, 2023.
, “MRI Visible Perivascular Spaces and the Risk of Incident Mild Cognitive Impairment in a Community Sample.”, J Alzheimers Dis, vol. 96, no. 1, pp. 103-112, 2023.
, “Multi-Site Cross-Site Inter-Rater and Test-Retest Reliability and Construct Validity of the MarkVCID White Matter Hyperintensity Growth and Regression Protocol.”, J Alzheimers Dis, vol. 96, no. 2, pp. 683-693, 2023.
, “Proteome Network Analysis Identifies Potential Biomarkers for Brain Aging.”, J Alzheimers Dis, vol. 96, no. 4, pp. 1767-1780, 2023.
, “Association of Carotid Intima Media Thickening with Future Brain Region Specific Amyloid-β Burden.”, J Alzheimers Dis, vol. 89, no. 1, pp. 223-232, 2022.
, “Associations Between Brainstem Volume and Alzheimer's Disease Pathology in Middle-Aged Individuals of the Framingham Heart Study.”, J Alzheimers Dis, vol. 86, no. 4, pp. 1603-1609, 2022.
, “Associations of Pulmonary Function with MRI Brain Volumes: A Coordinated Multi-Study Analysis.”, J Alzheimers Dis, vol. 90, no. 3, pp. 1073-1083, 2022.
, “Insulin-Like Growth Factor, Inflammation, and MRI Markers of Alzheimer's Disease in Predominantly Middle-Aged Adults.”, J Alzheimers Dis, vol. 88, no. 1, pp. 311-32, 2022.
, “Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, and Regional Amyloid-β and Tau Pathology in Middle-Aged Adults: The Framingham Study.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1371-1383, 2022.
, “Accelerometer-Measured, Habitual Physical Activity and Circulating Brain-Derived Neurotrophic Factor: A Cross-Sectional Study.”, J Alzheimers Dis, vol. 85, no. 2, pp. 805-814, 2021.
, “Association of Midlife Depressive Symptoms with Regional Amyloid-β and Tau in the Framingham Heart Study.”, J Alzheimers Dis, vol. 82, no. 1, pp. 249-260, 2021.
, “Plasma EFEMP1 Is Associated with Brain Aging and Dementia: The Framingham Heart Study.”, J Alzheimers Dis, vol. 85, no. 4, pp. 1657-1666, 2021.
, “Methionine Sulfoxide Reductase-B3 Risk Allele Implicated in Alzheimer's Disease Associates with Increased Odds for Brain Infarcts.”, J Alzheimers Dis, vol. 68, no. 1, pp. 357-365, 2019.
, “Genetic Interaction with Plasma Lipids on Alzheimer's Disease in the Framingham Heart Study.”, J Alzheimers Dis, vol. 66, no. 3, pp. 1275-1282, 2018.
, “Immunohistochemical Analysis of Activin Receptor-Like Kinase 1 (ACVRL1/ALK1) Expression in the Rat and Human Hippocampus: Decline in CA3 During Progression of Alzheimer's Disease.”, J Alzheimers Dis, vol. 63, no. 4, pp. 1433-1443, 2018.
, “Methionine Sulfoxide Reductase-B3 (MsrB3) Protein Associates with Synaptic Vesicles and its Expression Changes in the Hippocampi of Alzheimer's Disease Patients.”, J Alzheimers Dis, vol. 60, no. 1, pp. 43-56, 2017.
, “Association of Physical Function with Clinical and Subclinical Brain Disease: The Framingham Offspring Study.”, J Alzheimers Dis, vol. 53, no. 4, pp. 1597-608, 2016.
, “Association of Serum Vitamin D with the Risk of Incident Dementia and Subclinical Indices of Brain Aging: The Framingham Heart Study.”, J Alzheimers Dis, vol. 51, no. 2, pp. 451-61, 2016.
, “Evaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimer's Disease.”, J Alzheimers Dis, vol. 53, no. 3, pp. 921-32, 2016.
, “Interaction Between Midlife Blood Glucose and APOE Genotype Predicts Later Alzheimer's Disease Pathology.”, J Alzheimers Dis, vol. 53, no. 4, pp. 1553-62, 2016.
, “Lifelong Reading Disorder and Mild Cognitive Impairment: Implications for Diagnosis.”, J Alzheimers Dis, vol. 50, no. 1, pp. 41-5, 2016.
,